Patents by Inventor Xiangjian WANG

Xiangjian WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinoline derivative for treatment of triple-negative breast cancer
    Patent number: 11554115
    Abstract: The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 17, 2023
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xin Tian, Peng Lv, Ling Yang, Xiangjian Wang, Xiquan Zhang, Shanchun Wang, Xunqiang Wang, Hai Jiang
  • Bicylic compound acting as an inhibitor
    Patent number: 11466024
    Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: October 11, 2022
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Medshine Discovery Inc.
    Inventors: Kevin X Chen, Kai Zhou, Yanxin Yu, Boyu Hu, Linghui Wu, Xiaoyuan Chen, Jiangfeng Lin, Haomin Chen, Xiangjian Wang, Xiquan Zhang, Xin Tian, Hongjiang Xu
  • THERAPEUTIC COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
    Publication number: 20220160700
    Abstract: The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.
    Type: Application
    Filed: July 18, 2019
    Publication date: May 26, 2022
    Inventors: Xin TIAN, Chen SHEN, Peng LYU, Xiangjian WANG, Xiquan ZHANG, Zheng LIU, Yu XIA, Xiaoping JIN, Baiyong LI, Zhongmin Maxwell WANG, Baohui HAN, Tianqing CHU, Hua ZHONG, Rong LI
  • QUINOLINE DERIVATIVE FOR TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
    Publication number: 20200405709
    Abstract: The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor.
    Type: Application
    Filed: March 13, 2019
    Publication date: December 31, 2020
    Inventors: Xin TIAN, Peng LV, Ling YANG, Xiangjian WANG, Xiquan ZHANG, Shanchun WANG, Xunqiang WANG, Hai JIANG
  • BICYLIC COMPOUND ACTING AS AN INHIBITOR
    Publication number: 20200231597
    Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 23, 2020
    Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Kevin X CHEN, Kai ZHOU, Yanxin YU, Boyu HU, Linghui WU, Xiaoyuan CHEN, Jiangfeng LIN, Haomin CHEN, Xiangjian WANG, Xiquan ZHANG, Xin TIAN, Hongjiang XU
  • Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
    Patent number: 10561647
    Abstract: Provided in the present invention are a use of quinoline derivatives for treating oesophageal cancer and a treatment method, a pharmaceutical composition and a kit thereof. The 1-[[[4-(4-fluoro-2-methyl-1H-indole-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine provided by the present invention can effectively treat oesophageal cancer, and reduce the sum of the diameters of patient's target lesions.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 18, 2020
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Xunqiang Wang, Ling Yang, Zhongnan Xu, Xiangjian Wang, Wenjun Geng
  • Use Of Quinoline Derivatives For Treating Oesophageal Cancer And Treatment Method, Pharmaceutical Composition And Kit Thereof
    Publication number: 20190022082
    Abstract: Provided in the present invention are a use of quinoline derivatives for treating oesophageal cancer and a treatment method, a pharmaceutical composition and a kit thereof. The 1-[[[4-(4-fluoro-2-methyl-1H-indole-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine provided by the present invention can effectively treat oesophageal cancer, and reduce the sum of the diameters of patient's target lesions.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Inventors: Xunqiang WANG, Ling YANG, Zhongnan XU, Xiangjian WANG, Wenjun GENG